Citi analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $193.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Oppenheimer Upgrades Ascendis Pharma (ASND) to OutperformSeptember 5, 2024 6:54 AM Ascendis Pharma (ASND) PT Lowered to $174 at JefferiesSeptember 4, 2024 5:18 AM Ascendis Pharma (ASND) PT Lowered to $180 at Goldman SachsSeptember 4, 2024 5:06 AM Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlookSeptember 3, 2024 5:15 PM Form 6-K Ascendis Pharma A/S For: Sep 03September 3, 2024 5:15 PM Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementSeptember 3, 2024 5:14 PM Form 6-K Ascendis Pharma A/S For: Sep 03September 3, 2024 5:12 PM Form 6-K Ascendis Pharma A/S For: Jun 30September 3, 2024 5:11 PM Ascendis Pharma (ASND) and Royalty Pharma (RPRX) Enter $150M Royalty Funding AgreementSeptember 3, 2024 5:07 PM Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementSeptember 3, 2024 5:06 PM Ascendis Pharma Reports Second Quarter 2024 Financial ResultsSeptember 3, 2024 5:04 PM